Delivery Order SPE2DR25D9331-SPE2DR26FQPU7
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $27,905.88 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, issued on November 18, 2025, with an ultimate completion date of December 10, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement....
- The Defense Logistics Agency awarded a $77,830.30 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. The delivery order was issued on October 20, 2025, with an ultimate completion date of November 10, 2025, and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This...
- The Defense Logistics Agency awarded a $41,441.33 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. This firm fixed-price delivery order, issued on November 7, 2025, with an ultimate completion date of December 2, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The...
- The Defense Logistics Agency awarded a $79,430.86 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Perjeta 420 mg/14 mL vials. The award, issued on November 13, 2025, with an ultimate completion date of December 5, 2025, carries no set-aside designation and was issued without subcontractor involvement. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $9,301.96 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta (pertuzumab) 420 mg/14 mL vials. This firm fixed-price delivery order, issued on November 17, 2025, with an ultimate completion date of December 9, 2025, was awarded without set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal...
- The Defense Logistics Agency issued a firm fixed-price delivery order valued at $46,509.80 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The award was issued on November 13, 2025, with an ultimate completion date of December 5, 2025, and carries no set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $63,801.78 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, awarded on August 7, 2025, with an ultimate completion date of August 28, 2025, represents a specific supply requirement fulfilled under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA. The...
- The Defense Logistics Agency awarded a $27,343.62 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The contract, issued on May 6, 2025, with an ultimate completion date of May 28, 2025, represents a focused procurement action without set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,229.08 to DMS Pharmaceutical Group Inc. on August 19, 2025, for the supply of Perjeta 420 mg/14 mL vials. This firm fixed-price delivery order, with an ultimate completion date of September 10, 2025, will be performed at the vendor's location in Park Ridge, Illinois. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on its merits as a woman-owned small business pharmaceutical...
- The Defense Logistics Agency (DLA) issued a delivery order valued at $36,458.16 to DMS Pharmaceutical Group Inc. on September 17, 2025, for the supply of Perjeta (pertuzumab) 420 mg/14 mL vials. This firm fixed-price delivery order is expected to be completed by October 8, 2025, with fulfillment to occur at the contractor's location in Park Ridge, Illinois. The award was made without set-aside designation, and DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler,...
- SPE2DR25D9331Indefinite Delivery Contract
- SPE2DR25D9331-SPE2DR26FQPU7Delivery Order
The Defense Logistics Agency (DLA) awarded a $139,529.40 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta (420 mg/14 mL vials). The delivery order, issued on November 20, 2025, with an ultimate completion date of December 12, 2025, carries no set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group serves as the prime contractor with no identified subcontractors. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The parent contract, awarded on November 13, 2025, carries a $499.999 billion ceiling value and extends through December 31, 2036, positioning DMS Pharmaceutical Group as a critical regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy. The company's established distribution of specialized pharmaceuticals—including oncology treatments, biologics, vaccines, and medical consumables—to Department of Defense healthcare facilities worldwide reflects its essential role in supporting military medical supply requirements globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $139.5k | 11/20/25 |